Ardelyx Q1 product revenue $45.6M (IBSRELA $28.4M, XPHOZAH $15.2M); net loss $26.5M

ARDELYX, INC.

2024-Q1 EPS reported -$0.11 revenue$46,023,000

Q1 product-related revenue $45.6M: IBSRELA $28.4M (+149% YoY), XPHOZAH $15.2M (first full quarter after Oct 2023 approval).
Net loss $26.5M ($0.11/sh) vs $26.8M ($0.13/sh) in Q1 2023; cash & investments $202.6M.
Full-year 2024 IBSRELA net sales guidance raised to $140M-$150M.
SG&A expenses $53.0M (+$26.2M YoY) due to commercialization of both products.
Appointed Mike Kelliher as EVP Corporate Development and Strategy in March 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARDELYX, INC. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 2, 2024, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-019986

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.